Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies

Oliveira, Vinicius Fernandes De; Sousa, Graziella Ribeiro de; Santos, Antônio Carlos dos; Saggioro, Fabiano Pinto; Machado, Hélio Rubens; Oliveira, Ricardo Santos de; Tone, Luíz Gonzaga; Valera, Elvis Terci

doi:10.1007/s00381-020-04852-8

Cited by 6 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies reported on clinical presentation and/or survival [66][67][68][69][70][71][72][73][74][75][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123]. Survival is discussed below with treatment regimens in a separate section.…”

Section: Baseline Information and Clinical Presentation Of Patients W...mentioning

confidence: 99%

H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options

et al. 2023

View full text Add to dashboard Cite

The 2021 World Health Organization Classification of Tumors of the Central Nervous System reflected advances in understanding of the roles of oncohistones in gliomagenesis with the introduction of the H3.3-G34R/V mutant glioma to the already recognized H3-K27M altered glioma, which represent the diagnoses of pediatric-type diffuse hemispheric glioma and diffuse midline glioma, respectively. Despite advances in research regarding these disease entities, the prognosis remains poor. While many studies and clinical trials focus on H3-K27M-altered-glioma patients, those with H3.3-G34R/V mutant gliomas represent a particularly understudied population. Thus, we sought to review the current knowledge regarding the molecular mechanisms underpinning the gliomagenesis of H3.3-G34R/V mutant gliomas and the diagnosis, treatment, long-term outcomes, and possible future therapeutics.

show abstract

Section: Baseline Information and Clinical Presentation Of Patients W...mentioning

confidence: 99%

H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Molecular biology studies indicated that mutations in histone (H3) and ACVR1 [25], H3F3A / K27M and G34R / V [26] may be potential therapeutic targets [27].…”

Section: Treatmentmentioning

confidence: 99%

Brainstem tumors in children: a review

Ballestero

Furlanetti

Oliveira

2021

Arch Pediat Neurosurg

Self Cite

View full text Add to dashboard Cite

The brainstem is defined as the portion of the neural axis between the diencephalon and the cervical spinal cord. Brainstem gliomas (BSGs) can occur anywhere within this region and account for 10% to 15% of primary pediatric intracranial tumors. The development of neuroimaging allied to the refinement of surgical tools, such as improved magnification and visualization of the surgical field with more powerful surgical microscopes and sources of light, followed by the introduction of ultrasonic aspirator, anesthetic and intraoperative neurophysiological monitoring provided the neurosurgeon with conditions for a much safer surgical management of these tumors. This article reviews the current state of knowledge with regard to tumors arising in the brain stem in children, the therapeutic options available and provides recommendations with regard to management.

show abstract